1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

ETS6103 is being developed by e-Therapeutics for the treatment of MDD in patients who have not responded adequately to first-line therapy with an SSRI. ETS6103 is a controlled-release formulation of tramadol (e-Therapeutics, press release, October 31, 2013). Tramadol is a centrally acting synthetic analgesic compound, which is indicated for the treatment of moderate-to-severe pain.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on ETS6103 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for ETS6103 for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of ETS6103 performance
- Obtain sales forecast for ETS6103 from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Table Of Contents

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023
1 Table of Contents

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Classification 14
3.3 Symptoms and Subtypes of Major Depressive Disorder 16
3.4 Prognosis 17
3.5 Quality of Life 17
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 19
4.1.3 Clinical Practice 22
5 Competitive Assessment 27
5.1 Overview 27
6 Unmet Needs and Opportunities 29
6.1 Overview 29
6.2 More Effective Pharmacotherapies 30
6.2.1 Unmet Needs 30
6.2.2 Gap Analysis 31
6.2.3 Opportunities 32
6.3 More Favorable Side Effect Profiles 32
6.3.1 Unmet Needs 32
6.3.2 Gap Analysis 33
6.3.3 Opportunities 33
6.4 Rapid Onset of Antidepressant Effects 34
6.4.1 Unmet Needs 34
6.4.2 Gap Analysis 34
6.4.3 Opportunities 34
6.5 Personalized Treatment Approach 35
6.5.1 Unmet Needs 35
6.5.2 Gap Analysis 36
6.5.3 Opportunities 36
7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising Drugs in Clinical Development 37
8 ETS6103 40
8.1 Overview 40
8.2 Efficacy 41
8.3 Safety 42
8.4 Dosing and Formulation 42
8.5 Potential Clinical and Commercial Positioning 43
8.6 SWOT Analysis 44
8.7 Forecast 44
9 Appendix 46
9.1 Bibliography 46
9.2 Abbreviations 49
9.3 Methodology 51
9.4 Forecasting Methodology 51
9.4.1 Diagnosed MDD Patients 52
9.4.2 Percent of Drug-Treated Patients 52
9.4.3 General Pricing Assumptions 52
9.4.4 Generic Erosion 53
9.4.5 Pricing of Pipeline Agents 53
9.5 Physicians and Specialists Included in this Study 54
9.6 About the Authors 56
9.6.1 Analyst 56
9.6.2 Therapy Area Directors 56
9.6.3 Global Head of Healthcare 57
9.7 About GlobalData 58
9.8 Disclaimer 58

1.1 List of Tables

Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10) 15
Table 2: Subtypes of Major Depressive Disorder 16
Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria 18
Table 4: Treatment Guidelines for Major Depressive Disorder 20
Table 5: Most Prescribed Drugs for MDD by Class in the 7MM and Australia, 2013 22
Table 6: Leading Treatments for MDD, 2013 28
Table 7: Unmet Needs and Opportunities in MDD 30
Table 8: Comparison of Therapeutic Classes in Development for MDD, 2013 39
Table 9: Product Profile - ETS6103 41
Table 10: ETS6103 SWOT Analysis, 2014 44
Table 11: Global MDD Sales Forecasts ($m) for ETS6103, 2013-2023 45
Table 12: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 55

1.2 List of Figures

Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 14
Figure 2: Disease Management Model for Major Depressive Disorder 24
Figure 3: Major Depressive Disorder Treatment Algorithm 26
Figure 4: MDD - Phase IIb-III Pipeline, 2014 38
Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023 39
Figure 6: Clinical and Commercial Positioning of ETS6103 43

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

Related Market Segments :

Therapy
Depression

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.